Is there a need for novel cardiovascular risk factors?
Open Access
- 18 March 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (4) , 761-765
Abstract
Atherosclerosis is a multifactorial disease whose age of onset and progression are strongly influenced by inborn and acquired risk factors. Since the pioneering work of the Framingham study, many prospective population and clinical studies have identified a series of independent risk factors for myocardial infarction, stroke and peripheral vascular disease, among which the pre-existence of atherosclerotic vascular disease, age, male gender, a positive family history of premature atherosclerotic disease, smoking, diabetes mellitus, hypertension, hypercholesterolaemia, hypertriglyceridaemia and low HDL cholesterol are considered as classical risk factors. Moreover, several large randomized and prospective intervention studies have demonstrated that smoking cessation as well as anti-hypertensive and lipid-lowering drug therapies help to reduce cardiovascular morbidity and mortality by ∼30% in both secondary and primary prevention. Despite these advances, we currently witness a controversy concerning the introduction of novel risk factors into clinical practice, specifically lipoprotein(a) [Lp(a)], C-reactive protein (CRP), fibrinogen, homocysteine and microalbuminuria.Keywords
This publication has 56 references indexed in Scilit:
- European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)European Heart Journal, 2003
- Emerging Risk Factors for Atherosclerotic Vascular DiseaseJAMA, 2003
- Prevalence of Conventional Risk Factors in Patients With Coronary Heart DiseaseJAMA, 2003
- Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease EventsJAMA, 2003
- Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohortsEuropean Heart Journal, 2003
- Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Münster Study (PROCAM) using neural networksInternational Journal of Epidemiology, 2002
- C-Reactive Protein — To Screen or Not to Screen?New England Journal of Medicine, 2002
- Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) StudyCirculation, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Prediction of Coronary Heart Disease Using Risk Factor CategoriesCirculation, 1998